A Phase 4 interventional study of recombinant human hyaluronidase in Dehydration, sponsored by Halozyme Therapeutics. Completed at 25 sites in United States. Open to participants aged 30 Days to 10 Years. Per ClinicalTrials.gov, last updated 2018-11-07.
Sponsored by Halozyme Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Dehydration with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Dehydration · United States.
Among the 87 studies in Dehydration with a site in United States, this one is the 7th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 7th registered.
201 studies on the registry are indexed under Dehydration; 28 are open to participants now.
Browse Dehydration studies →7 of the 87 studies in Dehydration with a site in United States are open now. Recruiting first, the newest first:
State University of New York at Buffalo · Sites in United States
Ages 18–60
PepsiCo Global R&D · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Duquesne University · Sites in United States
Ages 60+ · Healthy volunteers
University of Iowa · Sites in United States
Ages 18–60
Arizona State University · Sites in United States
Ages 20–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Dehydration studies recruiting now, 7 (47%) set no upper age limit and 7 (47%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 30 Days to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3 · Phase 4 6
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 44 across 145 interventional studies indexed under Dehydration.
Median enrollment 30 across the 74 interventional studies, 82 across the 13 observational. Of the 73 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 87 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 1 study filed under Dehydration — fewer than ten, so there is no comparison to draw.
5 of the studies in Dehydration with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07653620PepsiCo Global R&DHydration & Female Life Stages | 2026-11 |
| NCT06847256University of IowaGenetic Risk Factor for Heat Stroke | 2026-12 |
| NCT07641361State University of New York at BuffaloHydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy | 2027-02-01 |
| NCT07658820Arizona State UniversityThe Role of Carbohydrate Blends and Electrolytes on Physical and Mental Performance During Cycling in the Heat | 2027-03-30 |
| NCT02253238M.D. Anderson Cancer CenterSensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 87 studies in Dehydration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized (1:1 ratio) study of subcutaneous (SC) versus intravenous (IV) fluid rehydration in mildly to moderately dehydrated pediatric patients.
This is a prospective, randomized (1:1 ratio), open-label, parallel group, multicenter, multi-national, study of SC versus IV fluid rehydration in mildly to moderately dehydrated pediatric patients treated in the Emergency Department (ED), inpatient pediatric unit, and/or outpatient urgent care facility. It is expected that up to 186 patients, in order to achieve 148 evaluable patients, will be randomized in a 1:1 ratio to receive isotonic fluid rehydration by either SC administration with hylenex (150 Units) or IV without hylenex.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)
Drug: recombinant human hyaluronidase
Isotonic fluid rehydration by IV
Drug: recombinant human hyaluronidase
150 Units in 1 mL
Also known as: Hylenex
Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Randomized Participants
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for Non-rescued Participants
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Total Volume of Fluid Administered at a Single Infusion Site, From the Start to the Cessation of Fluid Administration, for All Rescued Participants
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Randomized Participants Achieving > 200 mL
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the Food and Drug Administration (FDA) removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for Non-rescued Participants Achieving > 200 mL
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Total Volume of Fluid Administered at All Infusion Sites, From the Start to the Cessation of Fluid Administration, for All Rescued Participants Achieving > 200 mL
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Flow Rate, Delivered Per Unit Time, for All Randomized Participants
The mean flow rate was averaged over any 60-minute period of time.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Flow Rate, Delivered Per Unit Time, for All Non-rescued Participants
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Flow Rate, Delivered Per Unit Time, for All Rescued Participants
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Randomized Participants
The mean flow rate was averaged over any 60-minute period of time.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Non-rescued Participants
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Flow Rate, Delivered by Volume Per Unit Body Weight Per Unit Time, for All Rescued Participants
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants Achieving a Maximum Flow Rate of > 2 Milliliters Per Minute (mL/Min), as an Indication of Successful Hydration
The maximum flow rate was averaged over any 60-minute period of time.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants Administered at Least 200 Milliliter (mL) Total Volume at a Single Infusion Site, From the Start to the Cessation of Fluid Administration
The number of participants administered at least 20 mL total volume was assessed.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants With the Indicated Type of Adverse Events
Adverse events (AEs) are defined as any untoward medical occurrence in a participant administered a product, which did not necessarily have a causal relationship with the treatment. Treatment-emergent adverse events (TEAEs) are defined as those events that occurred on or after the first injection device insertion attempt.
Time frame: up to 7 days after hospital discharge
Number of Participants With Normal Physical Examination Findings at Baseline That Shifted to Abnormal at the End of Fluid Administration
Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion. Not Rel Dehy = Abnormal, Not Related to Dehydration; Rel Dehy = Abnormal, Related to Dehydration. The investigator assessed findings as abnormal.
Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Change From Baseline in Heart Rate
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.
Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Change From Baseline in Respiratory Rate
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.
Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.
Time frame: Baseline; after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Mean Change From Baseline in the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale Score
The infusion site was assessed for pain at two time points: after placement of the infusion device but before fluid infusion and at the end of infusion. Pain was recorded using the FLACC pain scale for children less than 3 years of age. Scores on the scale ranged from 0 (no hurt) to 10 (hurt worst).
Time frame: Before infusion (Baseline); after infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants With the Indicated Type of Fluid Administered
Data are reported for the initial fluid administered.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Infusion Duration During the Initial Infusion
Infusion duration was assessed as a measure of the time required to complete the initial infusion of 20 mL/kg.
Time frame: first hour of infusion
Change From Baseline in Hydration Status According to the Gorelick Assessment at the End of Fluid Infusion
Hydration status was assessed clinically using the Gorelick 10-item scale: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate, and capillary refill time at the fingertip. Scores ranged from 0 (less severe impairment) to 10 (more severe impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; during the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Percent Change From Baseline in Body Weight
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value) \* 100.
Time frame: Baseline; during the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants With the Indicated Type of Rescue Route Therapy Administered
Participants for whom parenteral access by the randomized route of administration could not be achieved after a reasonable number of attempts and for whom the investigator had deemed the access by that route a failure were expected to receive fluid administration by other means, designated as "rescue route" for the purpose of this study. This rescue route may have included venous cut-down, central venous line, interosseous access, etc., and for those participants initially randomly assigned to IV fluid administration, SC fluid administration by hylenex-facilitated infusion.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants Classified With the Indicated Healthcare Provider Responses to the Questions Comprising the Healthcare Provider Global Satisfaction Questionnaire
A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Was the participant successfully hydrated using the randomized route of administration?; Question 2: Overall, was the procedure of fluid infusion easy to perform?; Question 3: Were there any unacceptable side effects from the therapy?; Question 4: Would you consider using this hydration therapy for this indication in the future?
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants Classified With the Indicated Healthcare Provider Responses to the Question: How Does This Therapy Compare to Your Experience With IV (for SC Group) / SC (for IV Group) Therapy?
A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV).
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants Classified With the Indicated Parent/Guardian Responses to the Questions Comprising the Parent / Guardian Global Satisfaction Questionnaire
A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Do you believe the method of therapy was successful in your child's rehydration?; Question 2: Have you or your child ever previously had IV fluids (for SC Group) / SC fluids (for IV Group)?; Question 3: If the response to Question 2 was "yes," how does this compare to prior experience with IV (for SC Group) / SC (for IV Group)?; Question 4: Should your child(ren) need rehydration treatment in the future, would you opt for this procedure?; Question 5: Should you need rehydration treatment in the future, would you opt for this procedure?; Question 6: What is your global satisfaction with the study procedure?
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants With the Indicated Number of Different Anatomical Administration Sites Needed After the Start of Fluid Administration
In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants Experiencing Reductions in Flow Rate
In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.
Time frame: During the infusion (single bolus dose of hylenex [1 hr], followed by subcutaneous fluid for 1 hour to 72 hours)
Number of Participants Who Received Needle Placement by People With the Indicated Level of Staff Training
Data were collected for the level of staff training for the person who performed the needle placement.
Time frame: average of approximately 3 minutes
Number of Participants for Which the Indicated Number of Additional Personnel Was Involved in Needle Placement
Data were collected for the number of additional personnel involved in needle placement.
Time frame: average of approximately 3 minutes
Time From the Start of Infusion to the Time of Emergency Department (ED) Discharge
Data are reported from the start of infusion to the time of ED discharge.
Time frame: up to approximately 26 hours
Time From Randomization to the First Drop of Fluid Infusion
Data are reported for the time from randomization to the start of fluid infusion for all randomized participants.
Time frame: up to approximately 110 and 220 minutes for the SC and IV arms, respectively
Number of Participants With the Indicated Number of Needle Stick Attempts Needed to Initiate Fluid Administration
Data are reported for the number of needle stick attempts needed to initiate fluid administration.
Time frame: average of approximately 3 minutes
Number of Participants for Which the Indicated Type of Infusion Device Was Used
Data are reported for the type of infusion device used.
Time frame: average of approximately 3 minutes
Number of Participants for Which the Indicated Gauge for Infusion Device Was Used
Data are reported for the gauge of infusion device used.
Time frame: average of approximately 3 minutes
Number of Participants Discharged From the ED to Home or the Hospital
Participants were discharged from the ED to home or the hospital to continue hydration therapy.
Time frame: up to approximately 26 hours
Number of Participants With the Indicated Reason for Rehospitalization Within 48 and 72 Hours After Discharge
Participants were discharged from the ED to home or the hospital to continue hydration therapy.
Time frame: from randomization up to approximately 98 hours
| Milestone | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Started | 73 | 75 |
| Initial fluids via randomized route | 73 | 59 |
| Initial fluids via subcutaneous rescue | 0 | 15 |
| No fluids received | 0 | 1 |
| Completed | 71 | 73 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Consent withdrawn | 0 | 2 |
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.
| milliliters | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Emergency department plus hospital stay | 365.0 ± 324.57 | 455.8 ± 597.43 |
| Emergency department stay only | 334.3 ± 226.4 | 299.6 ± 252.33 |
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
| milliliters | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued |
|---|---|---|
| Emergency department plus hospital stay | 365.0 ± 324.57 | 579.4 ± 618.49 |
| Emergency department stay only | 334.3 ± 226.4 | 380.8 ± 223.08 |
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
| milliliters | Intravenous Isotonic Fluid: SC Rescued |
|---|---|
| Emergency department plus hospital stay | 388.3 ± 281.13 |
| Emergency department stay only | 315.3 ± 150.38 |
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest.
| milliliters | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Emergency department plus hospital stay | 365.4 ± 324.21 | 455.8 ± 597.43 |
| Emergency department stay only | 334.7 ± 225.94 | 299.6 ± 252.33 |
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the Food and Drug Administration (FDA) removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.
No measurements were reported for this outcome.
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.
No measurements were reported for this outcome.
It was anticipated that most participants in this study would be hydrated through only one infusion site. For participants who received fluid at more than one administration site, a single infusion site was defined as the anatomical site at which the majority of the total infusion volume was infused. The term "anatomical site" was designated as: 1) the back; 2) left thigh; 3) right thigh; 4) abdomen; or 5) chest. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue. The label for hylenex indicated precautionary wording recommending an upper limit on the volume of fluid (200 mL) administered subcutaneously to infants less than 3 years of age. In October 2008, the FDA removed this wording from the label, thus negating the need for these data and associated analyses. The protocol was amended to reflect this label change; thus, this analysis was not conducted.
No measurements were reported for this outcome.
The mean flow rate was averaged over any 60-minute period of time.
| milliliters per hour | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Emergency department plus hospital stay | 183.8 ± 94.61 | 166.1 ± 142.52 |
| Emergency department stay only | 186.4 ± 92.21 | 179.6 ± 141.19 |
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
| milliliters per hour | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued |
|---|---|---|
| Emergency department plus hospital stay | 183.8 ± 94.61 | 211.1 ± 127.44 |
| Emergency department stay only | 186.4 ± 92.21 | 228.3 ± 118.82 |
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
| milliliters per hour | Intravenous Isotonic Fluid: SC Rescued |
|---|---|
| Emergency department plus hospital stay | 139.1 ± 80.27 |
| Emergency department stay only | 149.8 ± 79.53 |
The mean flow rate was averaged over any 60-minute period of time.
| milliliters per kilogram per hour | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Emergency department plus hospital stay | 15.4 ± 5.62 | 12.3 ± 9.50 |
| Emergency department stay only | 15.6 ± 5.33 | 13.3 ± 9.50 |
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
| milliliters per kilogram per hour | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued |
|---|---|---|
| Emergency department plus hospital stay | 15.4 ± 5.62 | 15.7 ± 7.80 |
| Emergency department stay only | 15.6 ± 5.33 | 17.1 ± 7.14 |
The mean flow rate was averaged over any 60-minute period of time. Participants randomized to receive intravenous isotonic fluid were permitted to receive subcutaneous fluid administration by hylenex-facilitated infusion as rescue.
| milliliters per kilogram per hour | Intravenous Isotonic Fluid: SC Rescued |
|---|---|
| Emergency department plus hospital stay | 14.4 ± 6.47 |
| Emergency department stay only | 15.4 ± 6.07 |
The maximum flow rate was averaged over any 60-minute period of time.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Number of Participants Achieving a Maximum Flow Rate of > 2 Milliliters Per Minute (mL/Min), as an Indication of Successful Hydration | 68 | 57 |
The number of participants administered at least 20 mL total volume was assessed.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Number of Participants Administered at Least 200 Milliliter (mL) Total Volume at a Single Infusion Site, From the Start to the Cessation of Fluid Administration | 18 | 27 |
Adverse events (AEs) are defined as any untoward medical occurrence in a participant administered a product, which did not necessarily have a causal relationship with the treatment. Treatment-emergent adverse events (TEAEs) are defined as those events that occurred on or after the first injection device insertion attempt.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| At least 1 AE | 73 | 68 |
| At least 1 infusion site AE | 73 | 63 |
| at least 1 AE related to infusion fluid | 72 | 32 |
| At least 1 AE related to hylenex | 67 | 14 |
Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion. Not Rel Dehy = Abnormal, Not Related to Dehydration; Rel Dehy = Abnormal, Related to Dehydration. The investigator assessed findings as abnormal.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Head, eyes, ears: Not Rel Dehy | 1 | 0 | 0 |
| Head, eyes, ears: Rel Dehy | 0 | 0 | 0 |
| Neck/upper airway: Not Rel Dehy | 0 | 0 | 0 |
| Neck/upper airway: Rel Dehy | 0 | 0 | 0 |
| Heart: Not Rel Dehy | 0 | 1 | 0 |
| Heart: Rel Dehy | 0 | 0 | 0 |
| Lungs: Not Rel Dehy | 0 | 0 | 0 |
| Lungs: Rel Dehy | 0 | 0 | 0 |
| Abdomen: Not Rel Dehy | 0 | 0 | 0 |
| Abdomen: Rel Dehy | 0 | 0 | 0 |
| Skin: Not Rel Dehy | 0 | 1 | 2 |
| Skin: Rel Dehy | 0 | 0 | 0 |
| Musculoskeletal: Not Rel Dehy | 0 | 0 | 0 |
| Musculoskeletal: Rel Dehy | 0 | 0 | 0 |
| Extremities: Not Rel Dehy | 0 | 0 | 0 |
| Extremities: Rel Dehy | 0 | 0 | 0 |
| Neurological: Not Rel Dehy | 1 | 0 | 0 |
| Neurological: Rel Dehy | 0 | 0 | 0 |
| Vascular/Circulatory: Not Rel Dehy | 0 | 0 | 0 |
| Vascular/Circulatory: Rel Dehy | 1 | 0 | 0 |
| Lymphatic: Not Rel Dehy | 0 | 0 | 0 |
| Lymphatic: Rel Dehy | 0 | 0 | 0 |
| Reproductive: Not Rel Dehy | 0 | 0 | 0 |
| Reproductive: Rel Dehy | 0 | 0 | 0 |
| Renal/Urinary: Not Rel Dehy | 0 | 0 | 0 |
| Renal/Urinary: Rel Dehy | 1 | 0 | 0 |
| Endocrine/Metabolism and Nutrition: Not Rel Dehy | 0 | 0 | 0 |
| Endocrine/Metabolism and Nutrition: Rel Dehy | 0 | 0 | 0 |
| Other: Not Rel Dehy | 0 | 0 | 0 |
| Other: Rel Dehy | 0 | 0 | 0 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.
| beats per minute | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Mean Change From Baseline in Heart Rate | -6.9 ± 17.38 | -4.8 ± 18.64 | -11.3 ± 24.68 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.
| breaths per minute | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Mean Change From Baseline in Respiratory Rate | -4.8 ± 9.76 | -1.3 ± 7.96 | -2.6 ± 13.36 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the time prior to the single site fluid infusion. End of infusion was defined as the end of infusion of the single site fluid infusion for participants who had more than one fluid infusion.
| millimeters of mercury (mmHg) | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Systolic blood pressure | 3.2 ± 16.15 | 1.1 ± 15.49 | -4.0 ± 24.17 |
| Diastolic blood pressure | -0.2 ± 12.43 | 0.7 ± 12.45 | -2.9 ± 23.07 |
The infusion site was assessed for pain at two time points: after placement of the infusion device but before fluid infusion and at the end of infusion. Pain was recorded using the FLACC pain scale for children less than 3 years of age. Scores on the scale ranged from 0 (no hurt) to 10 (hurt worst).
| score on a scale | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Mean Change From Baseline in the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale Score | -4.4 ± 3.45 | -5.2 ± 2.94 | -3.8 ± 2.11 |
Data are reported for the initial fluid administered.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Lactated Ringers | 28 | 9 | 6 |
| Normal saline (NS) | 44 | 49 | 9 |
| D5 1/2 NS without potassium chloride (KCL) | 0 | 1 | 0 |
| D5 1/2 NS with KCL | 0 | 0 | 0 |
| Other | 1 | 0 | 0 |
Infusion duration was assessed as a measure of the time required to complete the initial infusion of 20 mL/kg.
| hours | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Infusion Duration During the Initial Infusion | 1.0 ± 0.13 | 0.8 ± 0.42 |
Hydration status was assessed clinically using the Gorelick 10-item scale: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate, and capillary refill time at the fingertip. Scores ranged from 0 (less severe impairment) to 10 (more severe impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| score on a scale | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Change From Baseline in Hydration Status According to the Gorelick Assessment at the End of Fluid Infusion | -2.6 ± 1.26 | -2.2 ± 1.64 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value) \* 100.
| percent change | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Percent Change From Baseline in Body Weight | 2.9 ± 2.52 | 3.8 ± 15.17 |
Participants for whom parenteral access by the randomized route of administration could not be achieved after a reasonable number of attempts and for whom the investigator had deemed the access by that route a failure were expected to receive fluid administration by other means, designated as "rescue route" for the purpose of this study. This rescue route may have included venous cut-down, central venous line, interosseous access, etc., and for those participants initially randomly assigned to IV fluid administration, SC fluid administration by hylenex-facilitated infusion.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| hylenex-facilitated SC | 0 | 15 |
| Other type of rescue | 0 | 0 |
A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Was the participant successfully hydrated using the randomized route of administration?; Question 2: Overall, was the procedure of fluid infusion easy to perform?; Question 3: Were there any unacceptable side effects from the therapy?; Question 4: Would you consider using this hydration therapy for this indication in the future?
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Question 1 — Yes | 68 | 57 |
| Question 1 — No | 4 | 13 |
| Question 1 — Missing | 1 | 5 |
| Question 2 — Yes | 69 | 49 |
| Question 2 — No | 4 | 21 |
| Question 2 — Missing | 0 | 5 |
| Question 3 — Yes | 3 | 4 |
| Question 3 — No | 70 | 66 |
| Question 3 — Missing | 0 | 5 |
| Question 4 — Yes | 71 | 64 |
| Question 4 — No | 2 | 6 |
| Question 4 — Missing | 0 | 5 |
A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV).
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Effectiveness: Less Effective | 3 | 1 |
| Effectiveness: Same Effectiveness | 58 | 41 |
| Effectiveness: More Effective | 11 | 0 |
| Effectiveness: Missing | 1 | 0 |
| Degree of Difficulty: Less Difficult | 57 | 2 |
| Degree of Difficulty: Same Difficulty | 11 | 12 |
| Degree of Difficulty: More Difficult | 3 | 28 |
| Degree of Difficulty: Missing | 2 | 0 |
| Not applicable: no prior experience with alternate | 0 | 33 |
A global assessment of overall satisfaction with the rehydration therapy by healthcare provider was performed at the end of SC or IV fluid rehydration utilizing a simple questionnaire. There were separate questionnaires for the two types of rehydration (SC and IV). Question 1: Do you believe the method of therapy was successful in your child's rehydration?; Question 2: Have you or your child ever previously had IV fluids (for SC Group) / SC fluids (for IV Group)?; Question 3: If the response to Question 2 was "yes," how does this compare to prior experience with IV (for SC Group) / SC (for IV Group)?; Question 4: Should your child(ren) need rehydration treatment in the future, would you opt for this procedure?; Question 5: Should you need rehydration treatment in the future, would you opt for this procedure?; Question 6: What is your global satisfaction with the study procedure?
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Question 1, yes | 70 | 59 |
| Question 1, no | 3 | 8 |
| Question 1, missing | 0 | 8 |
| Question 2, yes | 47 | 2 |
| Question 2, no | 26 | 63 |
| Question 2, not done | 0 | 2 |
| Question 2, missing | 0 | 8 |
| Question 3, worse | 2 | 0 |
| Question 3, same | 9 | 2 |
| Question 3, better | 35 | 0 |
| Question 3, missing | 1 | 0 |
| Question 4, yes | 65 | 56 |
| Question 4, no | 4 | 11 |
| Question 4, not done | 2 | 0 |
| Question 4, unknown | 1 | 0 |
| Question 4, missing | 1 | 8 |
| Question 5, yes | 68 | 55 |
| Question 5, no | 4 | 12 |
| Question 5, not done | 1 | 0 |
| Question 5, missing | 0 | 8 |
| Question 6, very unsatisfied | 3 | 8 |
| Question 6, unsatisfied | 1 | 4 |
| Question 6, satisfied | 26 | 31 |
| Question 6, very satisfied | 43 | 24 |
| Question 6, missing | 0 | 8 |
In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| 1 administration site | 72 | 59 | 15 |
| 2 administration sites | 1 | 0 | 0 |
In the event that the degree of local infusion site swelling became unacceptable for any reason (e.g., a 30% or greater increase from the baseline circumference of the infused thigh or in the clinical judgment of the investigator), the infusion rate was decreased or the infusion site was changed.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Number of Participants Experiencing Reductions in Flow Rate | 43 | 39 |
Data were collected for the level of staff training for the person who performed the needle placement.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Physician | 28 | 4 | 1 |
| Registered nurse | 35 | 48 | 10 |
| Physician assistant | 2 | 2 | 1 |
| Nurse practitioner | 6 | 0 | 0 |
| Licensed vocational nurse | 0 | 0 | 2 |
| Other | 2 | 5 | 1 |
Data were collected for the number of additional personnel involved in needle placement.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| 0 | 20 | 1 | 1 |
| 1 | 36 | 34 | 5 |
| 2 | 14 | 20 | 7 |
| 3 | 3 | 3 | 2 |
| 4 | 0 | 1 | 0 |
Data are reported from the start of infusion to the time of ED discharge.
| hours | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Time From the Start of Infusion to the Time of Emergency Department (ED) Discharge | 4.0 ± 4.26 | 3.1 ± 1.92 | 4.7 ± 4.64 |
Data are reported for the time from randomization to the start of fluid infusion for all randomized participants.
| minutes | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Time From Randomization to the First Drop of Fluid Infusion | 37 (31 to 41) | 42.5 (37 to 52) |
Data are reported for the number of needle stick attempts needed to initiate fluid administration.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| 1 | 69 | 54 |
| 2 | 4 | 13 |
| 3 | 0 | 7 |
| >3 | 0 | 1 |
Data are reported for the type of infusion device used.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| Angiocatheter | 63 | 57 | 15 |
| Butterfly needle | 10 | 1 | 0 |
| Other | 0 | 1 | 0 |
Data are reported for the gauge of infusion device used.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid: Non-rescued | Intravenous Isotonic Fluid: SC Rescued |
|---|---|---|---|
| 20 | 2 | 0 | 0 |
| 22 | 28 | 22 | 5 |
| 23 | 4 | 1 | 0 |
| 24 | 31 | 33 | 10 |
| 25 | 8 | 2 | 0 |
| 26 | 0 | 1 | 0 |
Participants were discharged from the ED to home or the hospital to continue hydration therapy.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Home | 60 | 64 |
| Hospital | 13 | 10 |
Participants were discharged from the ED to home or the hospital to continue hydration therapy.
| Participants | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Retreatment for dehydration | 2 | 2 |
| Other | 7 | 8 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subcutaneous Hylenex | 1/73 (1.4%) | 3/73 (4.1%) | 73/73 (100%) |
| Intravenous Isotonic Fluid | 0/75 (0%) | 4/75 (5.3%) | 62/75 (82.7%) |
| Event | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Viral gastroenteritisInfections and infestations | 1/73 | 0/75 |
| PneumoniaInfections and infestations | 1/73 | 0/75 |
| Cardio-respiratory ArrestCardiac disorders | 1/73 | 0/75 |
| GastroenteritisInfections and infestations | 1/73 | 0/75 |
| PyrexiaGeneral disorders | 0/73 | 1/75 |
| Ongoing dehydrationMetabolism and nutrition disorders | 0/73 | 1/75 |
| Rotavirus infectionInfections and infestations | 0/73 | 1/75 |
| Kawasaki diseaseVascular disorders | 0/73 | 1/75 |
| Event | Subcutaneous Hylenex | Intravenous Isotonic Fluid |
|---|---|---|
| Infusion site swellingGeneral disorders | 59/73 | 16/75 |
| Infusion site painGeneral disorders | 57/73 | 59/75 |
| Infusion site erythemaGeneral disorders | 54/73 | 19/75 |
| Infusion site oedemaGeneral disorders | 5/73 | 1/75 |
| Infusion site haematomaGeneral disorders | 0/73 | 3/75 |
| PyrexiaGeneral disorders | 2/73 | 2/75 |
| Age, Continuous(years) | Subcutaneous Hylenex | Intravenous Isotonic Fluid | Total |
|---|---|---|---|
| Mean | 2.1 ± 1.72 | 2.4 ± 2.07 | 2.3 ± 1.91 |
| Sex: Female, Male(Participants) | Subcutaneous Hylenex | Intravenous Isotonic Fluid | Total |
|---|---|---|---|
| Female | 39 | 36 | 75 |
| Male | 34 | 39 | 73 |
| Race/Ethnicity, Customized(Participants) | Subcutaneous Hylenex | Intravenous Isotonic Fluid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 25 | 22 | 47 |
| White | 39 | 40 | 79 |
| Native Hawaiian or Pacific Islander | 0 | 1 | 1 |
| Unknown | 9 | 12 | 21 |
The record gives a start of Oct 2008, a primary completion of Nov 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 9 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)